Literature DB >> 11866465

Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo.

Kathleen Bove1, David W Lincoln, Min-Fu Tsan.   

Abstract

In vitro, resveratrol inhibited growth of 4T1 breast cancer cells in a dose- and time-dependent manner. In vivo, however, resveratrol had no effect on time to tumor take, tumor growth, or metastasis when administered intraperitoneally daily (1, 3, or 5 mg/kg) for 23 days starting at the time of tumor inoculation. Resveratrol had no effect on body weight, organ histology, or estrous cycling of the tumor-bearing mice. Resveratrol, therefore, is a potent inhibitor of 4T1 breast cancer cells in vitro; is nontoxic to mice at 1-5 mg/kg; and has no growth-inhibitory effect on 4T1 breast cancer in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866465     DOI: 10.1006/bbrc.2002.6554

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

Review 1.  Resveratrol, sirtuins, and the promise of a DR mimetic.

Authors:  Joseph A Baur
Journal:  Mech Ageing Dev       Date:  2010-02-26       Impact factor: 5.432

2.  Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.

Authors:  Nicolas G Azios; Suranganie F Dharmawardhane
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

3.  Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice.

Authors:  Hai-Bo Zhou; Juan-Juan Chen; Wen-Xia Wang; Jian-Ting Cai; Qin Du
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

Review 4.  Natural compounds as anticancer agents: Experimental evidence.

Authors:  Jiao Wang; Yang-Fu Jiang
Journal:  World J Exp Med       Date:  2012-06-20

5.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 6.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors α and β in breast cancer cells.

Authors:  Amruta Ronghe; Anwesha Chatterjee; Bhupendra Singh; Prasad Dandawate; Fatma Abdalla; Nimee K Bhat; Subhash Padhye; Hari K Bhat
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-09       Impact factor: 4.219

8.  EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase.

Authors:  Thejass Punathil; Trygve O Tollefsbol; Santosh K Katiyar
Journal:  Biochem Biophys Res Commun       Date:  2008-08-08       Impact factor: 3.575

9.  Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells.

Authors:  Yoo Jin Choi; Kwang Mo Yang; Sung Dae Kim; Young Hyun Yoo; Sang Wha Lee; Su Yeong Seo; Hongsuk Suh; Sung Tae Yee; Min Ho Jeong; Wol Soon Jo
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

10.  An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression.

Authors:  Seung Hun Jeong; In Sung Song; Hyoung Kyu Kim; Sung Ryul Lee; Suhee Song; Hongsuk Suh; Young Geol Yoon; Young Hyun Yoo; Nari Kim; Byoung Doo Rhee; Kyung Soo Ko; Jin Han
Journal:  Mol Cells       Date:  2012-10-18       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.